Publicações científicas

Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression

Unzu C(1), Melero I(2) [ES], Hervás-Stubbs S(3), Sampedro A(1), Mancheño U(1), Morales-Kastresana A(1), Serrano-Mendioroz I(1), de Salamanca RE(4), Benito A(5) [ES], Fontanellas A(6).
(1) Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain.
(2) [1] Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain [2] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain [3] Department of Oncology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain.
(3) [1] Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain [2] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
(4) Research Center, Hospital Universitario 12 de Octubre, University Complutense of Madrid, Spain.
(5) [1] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain [2] Department of Radiology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain.
(6) [1] Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain [2] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain [3] CIBERehd, University Clinic Navarra. Instituto de Salud Carlos III. Pamplona, Spain.

Revisão:Gene Therapy

Data: 30/Jun/2015

Oncologia Médica Radiología [ES]

Resumo

Helper-dependent adenoviral (HDA) vectors constitute excellent gene-therapy tools for metabolic liver diseases. We have previously shown that an HDA vector encoding human porphobilinogen deaminase (PBGD) corrects acute intermittent porphyria mice.

Now, six non-human primates were injected in the left hepatic lobe with the PBGD-encoding HDA vector to study levels and persistence of transgene expression. Intrahepatic administration of 5 × 1012 viral particles/kg (1010 infective units/kg) of HDA only resulted in transient (≈14 weeks) transgene-expression in one out of three individuals.

In contrast, a more prolonged 90-day immunosuppressive regimen (tacrolimus, mycophenolate, rituximab and steroids) extended meaningful transgene expression for over 76 weeks in two out of two cases. Transgene-expression under immunosuppression reached maximum levels 6 weeks after HDA administration and gradually declined reaching a stable plateau within the therapeutic range for acute porphyria. The non-injected liver lobes also expressed the transgene because of vector circulation. Immunosuppression controlled anti-capsid T-cell responses and decreased the induction of neutralizing antibodies. Re-administration of HDA-hPBGD at week +78 achieved therapeutically meaningful transgene-expression only in those animals receiving immunosuppression again at the time of this second vector exposure.

Overall, immunity against adenoviral capsids poses serious hurdles for long-term HDA-mediated liver transduction, which can be partially circumvented by pharmacological immunosuppression.Gene Therapy accepted article preview online, 30 June 2015. doi:10.1038/gt.2015.64.

CITAÇÃO DO ARTIGO  Gene Ther. 2015 Jun 30. doi: 10.1038/gt.2015.64.

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra